469 related articles for article (PubMed ID: 25583377)
21. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
[TBL] [Abstract][Full Text] [Related]
22. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan.
Ogawa A; Ejiri K; Matsubara H
Life Sci; 2014 Nov; 118(2):414-9. PubMed ID: 24530872
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
24. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
[TBL] [Abstract][Full Text] [Related]
25. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension.
Zheng YG; Yang T; Xiong CM; He JG; Liu ZH; Gu Q; Zhao ZH; Ni XH
Heart Lung Circ; 2015 Jun; 24(6):566-72. PubMed ID: 25573235
[TBL] [Abstract][Full Text] [Related]
26. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
[TBL] [Abstract][Full Text] [Related]
27. Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity.
Favoino E; Prete M; Liakouli V; Leone P; Sisto A; Navarini L; Vomero M; Ciccia F; Ruscitti P; Racanelli V; Giacomelli R; Perosa F
Autoimmun Rev; 2024 Apr; 23(4):103514. PubMed ID: 38181859
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in pulmonary arterial hypertension with Dana Point group 1.
Adachi S; Hirashiki A; Nakano Y; Shimazu S; Murohara T; Kondo T
Life Sci; 2014 Nov; 118(2):404-9. PubMed ID: 24632476
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of high risk factors for patient death and its clinical characteristics on pregnancy associated with pulmonary arterial hypertension].
Bao Z; Zhang J; Yang D; Xu X
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):495-500. PubMed ID: 25327730
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Olsson KM; Delcroix M; Ghofrani HA; Tiede H; Huscher D; Speich R; Grünig E; Staehler G; Rosenkranz S; Halank M; Held M; Lange TJ; Behr J; Klose H; Claussen M; Ewert R; Opitz CF; Vizza CD; Scelsi L; Vonk-Noordegraaf A; Kaemmerer H; Gibbs JS; Coghlan G; Pepke-Zaba J; Schulz U; Gorenflo M; Pittrow D; Hoeper MM
Circulation; 2014 Jan; 129(1):57-65. PubMed ID: 24081973
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.
Lettieri CJ; Nathan SD; Barnett SD; Ahmad S; Shorr AF
Chest; 2006 Mar; 129(3):746-52. PubMed ID: 16537877
[TBL] [Abstract][Full Text] [Related]
33. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy.
Taguchi H; Kataoka M; Yanagisawa R; Kawakami T; Tamura Y; Fukuda K; Yoshino H; Satoh T
Circ J; 2012; 76(6):1494-500. PubMed ID: 22447010
[TBL] [Abstract][Full Text] [Related]
34. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
35. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.
Fisher MR; Mathai SC; Champion HC; Girgis RE; Housten-Harris T; Hummers L; Krishnan JA; Wigley F; Hassoun PM
Arthritis Rheum; 2006 Sep; 54(9):3043-50. PubMed ID: 16947776
[TBL] [Abstract][Full Text] [Related]
36. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.
Mathai SC; Bueso M; Hummers LK; Boyce D; Lechtzin N; Le Pavec J; Campo A; Champion HC; Housten T; Forfia PR; Zaiman AL; Wigley FM; Girgis RE; Hassoun PM
Eur Respir J; 2010 Jan; 35(1):95-104. PubMed ID: 19643943
[TBL] [Abstract][Full Text] [Related]
37. Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.
Hsu S; Kokkonen-Simon KM; Kirk JA; Kolb TM; Damico RL; Mathai SC; Mukherjee M; Shah AA; Wigley FM; Margulies KB; Hassoun PM; Halushka MK; Tedford RJ; Kass DA
Circulation; 2018 May; 137(22):2360-2370. PubMed ID: 29352073
[TBL] [Abstract][Full Text] [Related]
38. Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization.
Batal O; Khatib OF; Dweik RA; Hammel JP; McCarthy K; Minai OA
Am J Cardiol; 2012 May; 109(10):1514-20. PubMed ID: 22360818
[TBL] [Abstract][Full Text] [Related]
39. Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension.
Roofthooft MT; Douwes JM; Vrijlandt EJ; Berger RM
Am J Cardiol; 2013 Nov; 112(9):1505-9. PubMed ID: 23972345
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.
Ramjug S; Hussain N; Hurdman J; Elliot CA; Sabroe I; Armstrong IJ; Billings C; Hamilton N; Kiely DG; Condliffe R
Respirology; 2017 Feb; 22(2):372-377. PubMed ID: 27651181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
